Ad Scientiam
Ad Scientiam is a French digital health company developing CE-marked and FDA-registered Software as a Medical Device (SaMD) that uses smartphone sensors and proprietary algorithms to generate clinically validated digital biomarkers for monitoring multiple sclerosis, cystic fibrosis, and other serious diseases, serving pharmaceutical companies and patients.
- Company typePrivate
- Founded2013
- HeadquartersParis, France
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What Ad Scientiam does
Ad Scientiam is a French digital health company founded in 2013 that designs, validates, and commercializes Software as a Medical Device (SaMD) solutions measuring disease progression through digital biomarkers derived from continuous smartphone sensor data. Headquartered at the iPEPS Healthtech Hub of the Institut du Cerveau in Paris and born at Pitié-Salpêtrière hospital, the company targets pharmaceutical companies and patients living with serious neurological and chronic diseases, with its flagship MSCopilot® being the first CE-marked Class IIa SaMD for real-life self-assessment of multiple sclerosis (CE marked June 2025, FDA 510(k) registered 2025–2026). Its proprietary algorithms process 350+ digital biomarkers covering walking, vision, dexterity, and cognition, with outputs clinically validated against EDSS and MSFC-4 gold standards across the MS-DETECT (243 patients) and MS-FLOWER (62 patients in four US centers) studies.
The company operates a dual-track business model: MSCopilot is provided free of charge to patients and healthcare professionals via iOS and Android app stores, while revenue is generated through B2B licensing and clinical study services to pharmaceutical partners including Sanofi, Merck KGaA, and Vertex Pharmaceuticals. Ad Scientiam secured €5 million in funding from TechLife Capital in November 2025 to support expansion of its digital biomarker portfolio, entry into new therapeutic areas (including a generalized myasthenia gravis program with Merck KGaA launching 2026), and enhanced commercialization. The company is expanding its product surface with MuCopilot® for cystic fibrosis (70-patient clinical study planned, targeting Class IIa certification), opening a US subsidiary, and pursuing geographic expansion into the US and Germany. The company maintains ISO 13485 certification, GDPR-compliant data practices on EU-hosted Azure infrastructure, and CE/FDA regulatory clearances that create meaningful barriers to entry in the MS digital biomarker space.
Ad Scientiam firmographics
Firmographics- Name
- Ad Scientiam
- Legal name
- Ad Scientiam SAS
- Website
- https://adscientiam.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Ad Scientiam is a French digital health company developing CE-marked and FDA-registered Software as a Medical Device (SaMD) that uses smartphone sensors and proprietary algorithms to generate clinically validated digital biomarkers for monitoring multiple sclerosis, cystic fibrosis, and other serious diseases, serving pharmaceutical companies and patients.
- Ownership category
- akta.pro rank
Ad Scientiam industry classification
Industry- Product category
- Medical Device Software (Digital Health)
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391), Medical and Diagnostic Laboratories (62151), Computer Systems Design and Related Services (54151)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826), Services-Health Services (8000)
- akta.pro primary industry
- SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)
- akta.pro secondary industries
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), SaMD – Monitoring, Triage & Risk Stratification Software (HLACANAE), DTx/SaMD Regulatory, Quality & Compliance Software (QMS/ISO/FDA) (HLACANAN)
Keywords
Where Ad Scientiam is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
Ad Scientiam business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- B2B Licensing to Pharmaceutical Companies: Ad Scientiam generates revenue by providing its digital biomarker platforms (MSCopilot, MuCopilot) to pharmaceutical companies for use in clinical trials, drug development, and post-marketing surveillance. The company is used in several clinical studies and partners with pharma for regulatory-grade real-world data collection.
- Clinical Study Services: The company conducts clinical studies on behalf of pharmaceutical partners, providing digital measurement solutions and regulatory-grade data. Multiple studies are referenced including MS-DETECT, MS-FLOWER, and studies for Merck KGaA and Vertex.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Monthly | Free for patients and healthcare professionals |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
Ad Scientiam product offering
Product offeringCore offering
Ad Scientiam designs, validates, and commercializes Software as a Medical Device (SaMD) digital biomarkers that continuously measure disease progression in real-life conditions using smartphone sensor data processed by proprietary algorithms. Its flagship product MSCopilot® is a CE-marked (Class IIa) and FDA 510(k)-registered SaMD for self-assessment of Multiple Sclerosis patients, capturing more than 350 digital biomarkers across walking, vision, dexterity, and cognition. The portfolio also includes MuCopilot® for at-home cystic fibrosis monitoring and pipeline work in generalized myasthenia gravis with Merck KGaA.
Product overview
Ad Scientiam is a pioneer in digital biomarkers, designing, validating, and implementing Software as a Medical Devices (SaMD) that continuously measure disease progression in real life. The company's portfolio includes MSCopilot® (for Multiple Sclerosis, launched 2018, CE/FDA cleared) and MuCopilot® (for Cystic Fibrosis, in development). Both products use patients' smartphones to collect sensor data transformed by proprietary algorithms into clinically-validated digital biomarkers. Results are shared with healthcare professionals via secure dashboards. The company focuses on neuroscience (MS, neuromuscular diseases), mental disorders (treatment-resistant depression), and rare diseases (cystic fibrosis, hemophilia).
Differentiator
Problem solved
Functional benefit
Brands
- MSCopilot®: First CE-marked software medical device for real-life self-assessment of Multiple Sclerosis patients. Captures over 350 digital biomarkers on physiological and behavioral characteristics via smartphone. Currently has over 3,500 users.
- MuCopilot®
Products and services
- MSCopilot® Software as a Medical Device (SaMD) for real-life self-assessment of Multiple Sclerosis patients. Uses patients' smartphones to capture more than 350 digital biomarkers on physiological and behavioral characteristics, including walking, visual acuity, dexterity, and cognition, then processes them through proprietary algorithms to generate scores that correlate with clinical gold standards (MSFC-4, EDSS). Results are shared via secure dashboard with healthcare professionals to support clinical decision-making. CE-marked (Class IIa) and FDA 510(k) registered. Used by 3,500+ patients.
- MuCopilot® Software as a Medical Device (SaMD) dedicated to disease monitoring for cystic fibrosis. Measures respiratory function (phonation time), nocturnal cough, and endurance via smartphone sensors alone, enabling at-home monitoring between clinic visits. Currently in clinical development with a planned 70-patient study to correlate home measurements with clinical standards, developed in partnership with Vertex Pharmaceuticals and Société Française de la Mucoviscidose.
Quantifiable outcome
- MSCopilot digital biomarkers correlate significantly with clinical scores MSFC-4 and EDSS in MS-DETECT study (243 patients, interim analysis)
- +2 more outcomes
Companies that use Ad Scientiam
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles2 records
Ad Scientiam technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
Ad Scientiam partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core, major and supporting.
- Merck KGaAcoreAd Scientiam and Merck KGaA are collaborating on a prospective, multicenter pilot study starting in 2026 across several European countries to evaluate an investigational software medical device combining a mobile application, wearable, and ePROs to collect digital measures in real-life unsupervised conditions for monitoring generalized myasthenia gravis (gMG).
- SanoficoreSanofi supported the MS-FLOWER pilot (62 MS patients across 4 US centers in Austin, St. Louis, Oklahoma City, New Orleans) and the MS-DETECT (NCT05816122) international clinical study. First results of MS-FLOWER to be presented at AAN 2026. Sanofi is a key partner in clinical validation of MSCopilot.
- Vertex PharmaceuticalscoreVertex Pharmaceuticals partnered with Ad Scientiam and the Société Française de Mucoviscidose on the Mucolab project, an ambitious innovation to improve at-home follow-up of cystic fibrosis patients through new respiratory digital biomarkers. Vertex is a global biotech company focused on cystic fibrosis treatments.
- Société Française de Mucoviscidose (Cystic Fibrosis French Society)majorThe Société Française de Mucoviscidose partnered with Ad Scientiam and Vertex Pharmaceuticals on the Mucolab project to develop respiratory digital biomarkers for at-home cystic fibrosis monitoring.
- Microsoft (Azure Cloud)supportingAd Scientiam's website and data infrastructure are hosted on Microsoft's Azure cloud offering, geographically located within the European Union. Microsoft France is a certified health data host.
- BSI (Notified Body)supportingBSI is the Notified Body that granted Ad Scientiam its ISO 13485 'Medical devices - Quality management system' certification in August 2020.
- ANSM (Agence nationale de sécurité du médicament et des produits de santé)supportingAll Ad Scientiam Medical Devices are declared to the ANSM before being made available on the French market, in accordance with French medical device regulations.
Scale indicators6 records
Recent moves7 records
Expansion highlights4 records
Ad Scientiam competitors and assessment
Company assessmentDirect peers
- Medable: Medable provides decentralized clinical trial technology and eCOA/ePRO solutions used by pharma sponsors to capture patient data outside clinic visits. Directly comparable to Ad Scientiam's B2B pharma clinical-trial enablement model and target customer base.
- Koneksa Health: Koneksa develops digital biomarkers and remote patient monitoring tools used in clinical trials across therapeutic areas including neuroscience. Closely aligned to Ad Scientiam in technology (wearable/sensor-derived biomarkers), customer base (pharma), and validation model (clinical correlations).
- VivoSense: VivoSense specializes in wearable sensors and digital endpoints for clinical trials and drug development, with regulatory-grade sensor data analytics. Direct competitor in digital biomarker/SaMD solutions sold to pharma sponsors.
- Evidation Health: Evidation Health operates a digital health measurement platform that generates real-world evidence and digital biomarkers from consumer devices for pharma and life sciences clients. Highly comparable business model of consumer-grade data → regulatory-grade pharma evidence.
Emerging players
- Aparito: Aparito provides remote patient monitoring and digital endpoint solutions for rare disease and specialty pharma clinical trials. Comparable in disease-monitoring SaMD positioning and pharma B2B model, though focused on smaller patient populations.
- uMotif: uMotif offers a patient data capture platform (ePRO, eCOA) used in clinical trials across therapeutic areas. Adjacent peer in the decentralized clinical trial enablement space, with similar pharma customer base and disease-monitoring use cases.
Broad incumbents
- Roche (Flatiron Health): Roche operates a broad digital health portfolio including Flatiron Health (oncology real-world evidence) and mySugr (diabetes monitoring). As a major MS drug manufacturer and Ad Scientiam trust-signal partner, Roche represents both a potential customer and a competitive threat via in-house digital biomarker programs.
- Biogen: Biogen is a leading MS therapeutics company and listed as a trust-signal partner of Ad Scientiam. Competes indirectly through its own MS digital health initiatives and is simultaneously a potential enterprise customer for Ad Scientiam's MS monitoring solutions.
- Novartis: Novartis operates digital biomarker and decentralized trial programs through its pharma R&D organization and partners like Science 37. Comparable in disease area (MS via Kesimpta) and broad SaMD ambitions.
- Clario (ERT / Bioclinica): Clario (formed via ERT-Bioclinica merger) is a major provider of clinical trial endpoint technologies including eCOA, imaging, and digital biomarkers. Represents the broad incumbent player in the same pharma B2B SaMD-for-clinical-trials category.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Ad Scientiam social profiles
Digital presenceAd Scientiam compliance and trust
Trust signalCompliance3 records
Ad Scientiam financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ad Scientiam leadership team
Management profileNumber of profiles
Profiles5 records
Ad Scientiam subsidiaries and ownership
Company hierarchySubsidiaries1 record
Ad Scientiam funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ad Scientiam M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ad Scientiam
What does Ad Scientiam do?
Ad Scientiam designs, validates, and commercializes Software as a Medical Device (SaMD) digital biomarkers that continuously measure disease progression in real-life conditions using smartphone sensor data processed by proprietary algorithms. Its flagship product MSCopilot® is a CE-marked (Class IIa) and FDA 510(k)-registered SaMD for self-assessment of Multiple Sclerosis patients, capturing more than 350 digital biomarkers across walking, vision, dexterity, and cognition. The portfolio also includes MuCopilot® for at-home cystic fibrosis monitoring and pipeline work in generalized myasthenia gravis with Merck KGaA.
Is Ad Scientiam a public or private company?
Ad Scientiam is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ad Scientiam founded?
Ad Scientiam was founded in 2013. It employs 51 to 100 people.
Where is Ad Scientiam based?
Ad Scientiam is headquartered in Paris, France, in the Europe region.
How does Ad Scientiam make money?
Two revenue lines are on record. B2B Licensing to Pharmaceutical Companies are the primary driver. The others are clinical Study Services.
Who are Ad Scientiam's main competitors?
Direct peers on record are Medable, Koneksa Health, VivoSense and Evidation Health. Emerging players are Aparito and uMotif. Broad incumbents are Roche (Flatiron Health), Biogen, Novartis and Clario (ERT / Bioclinica).
Does Ad Scientiam have an API?
No public API is recorded for Ad Scientiam.
What industry is Ad Scientiam in?
Ad Scientiam's product category is Medical Device Software (Digital Health). Its primary akta.pro industry code is HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints, with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its NAICS code is 334510 and its SIC code is 3841.